Skyhawk Therapeutics
27 articles about Skyhawk Therapeutics
-
Skyhawk Therapeutics Announces Addition of World Leading SAB Head & New VP of Oncology Biology
7/8/2019
Tyler Jacks, Ph.D., head of the Koch Institute for Integrative Cancer Research at MIT, joins as Chair of Skyhawk's Scientific Advisory Board
-
Skyhawk and Merck will partner to discover and develop innovative RNA-binding small molecules that can form treatments for neurological diseases and cancer.
-
Skyhawk Therapeutics Announces Agreement with Takeda to Develop Novel Small Molecule RNA Splicing Modifiers for Neurodegenerative Diseases
5/6/2019
Skyhawk will use its SkySTAR™ platform to develop drug candidates directed to multiple targets for neurodegenerative diseases. In exchange Takeda will pay Skyhawk an upfront payment, future milestone payments and royalties.
-
BioSpace Movers and Shakers: Feb. 15
2/15/2019
Pharma and biotech companies strengthen their leadership teams with new hires and appointments at Cadent, bluebird, Abeona, Sanofi, and more. -
Pioneer in Taking RNA Therpeutics Through the Clinic Joins Skyhawk Therapeutics as Chief Medical Officer
2/12/2019
Skyhawk signals progression toward the clinical stage with the hire of CMO Dr. Roberto Guerciolini, M.D., who brings deep experience as a clinician who took several of the earliest RNA targeting drugs successfully to patients.
-
BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* no earlier than 2017.
-
Biogen and Skyhawk Therapeutics Announce Agreement to Develop Novel Small Molecule RNA Splicing Modifiers for Neurological Disease Targets
1/4/2019
Biogen made a one-time upfront $74 million payment to Skyhawk for research services and an exclusive license to therapeutic candidates for multiple sclerosis, spinal muscular atrophy and other neurological diseases to be developed using Skyhawk's SkySTAR™ platform